Polypeptide-polymer bioconjugates by Canalle, L.A. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/84183
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Polypeptide–polymer bioconjugates
Luiz A. Canalle, Dennis W. P. M. Lo¨wik and Jan C. M. van Hest*
Received 7th May 2009
First published as an Advance Article on the web 6th October 2009
DOI: 10.1039/b807871h
Creating bioconjugates by combining polymers with peptides and proteins is an emerging
multidisciplinary ﬁeld of research that has enjoyed increased attention within the scientiﬁc
community. This critical review provides an overview of the strategies employed for the
construction of these materials and will highlight the underlying synthetic methods used.
This review is therefore relevant for chemists, material scientists and chemical biologists
facing the challenge of constructing polypeptide–polymer bioconjugates in a controlled fashion
(269 references).
1. Introduction
Traditionally, synthetic polymers have mainly been exploited
for their structural properties and as such, have successfully
replaced natural materials in a wide variety of applications.
A reason for their success is that synthetic polymers can be
obtained in a large range of compositions and architectures,
which allows for a convenient ﬁne tuning of their properties.
However, even with the current synthetic techniques, there is
still limited control over monomer composition and molecular
weight. A synthetic polymer sample is therefore a mixture of
many diﬀerent macromolecules, which makes it diﬃcult to
translate information from the single polymer chain to the
polymeric ensemble.
On the other hand, naturally produced peptides or proteins
can be regarded as highly reﬁned polymers. They are mono-
disperse and have a precisely deﬁned primary sequence, which
allows them to hierarchically fold and organize into three-
dimensional structures. This permits polypeptides to exhibit
(bio)functional features like catalysis or receptor recognition.
As a downside to this delicate folding behaviour, proteins are
sensitive to temperature and pH changes. Furthermore, they
have limited solubility in organic solvents, are susceptible to
enzyme degradation, and their use in biomedical applications
can be restricted by their possible toxicity and undesired
elicited immune response.
In this review, we will focus on synthetic pathways that can
be used to combine synthetic polymers with proteins or
peptides. The resulting bioconjugates can synergistically
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combine the properties of the individual components and
overcome their separate limitations. The protein or peptide
element can impart (bio)functional properties to the bio-
conjugate, whereas the polymer component can improve
protein stability, solubility and biocompatibility. The synthetic
polymer can also introduce new properties such as self-assembly
and phase behaviour, and even modulate protein activity. This
emerging multidisciplinary ﬁeld has opened the door to a wide
range of applications which will be discussed throughout the
article and which have already been extensively reviewed in
recent literature.1–7 The main focus of this article, however, is
the chemistry and synthetic strategies that are involved in the
construction of these hybrid conjugates, and that have become
more selective and speciﬁc in recent years, resulting in better
deﬁned polypeptide–polymer bioconjugates.
1.1 Speciﬁcity
Most traditional conjugation methods rely on a nucleophilic
attack of a functional group of an amino acid side chain in the
polypeptide on an appropriate electrophilic centre within the
synthetic polymer. Due to the polyfunctional nature of
proteins and peptides, however, such approaches ultimately
lead to a mixture of products.
As a result, the search for more speciﬁc modiﬁcation methods
has been the topic of signiﬁcant academic research during the last
decade. Site-speciﬁc modiﬁcations would ﬁrst of all help with the
puriﬁcation and characterization of the obtained products,
because mixtures are avoided. Furthermore, if the modiﬁcation
is directed to a speciﬁc location, the protein activity might be
better preserved. For instance, the site for polymer conjugation
can be located far away from the active site to avoid interference
with the biological functioning of the protein. Alternatively, it
can also be located nearby, or even within the active site, in order
to control the biological activity of the protein.
No universal technique exists to date, but signiﬁcant advances
have been made in the development of more speciﬁc methods.8
When using naturally occurring functionalities in proteins or
peptides, there has been a trend to modify amino acid targets that
are less common. Alternatively, the conjugation step can be
carried out under conditions directing the availability of the
modiﬁcation sites. Examples are the use of protective groups on
peptides or the blockage of the active site of proteins with a
substrate during the conjugation reaction. In some cases,
biochemical approaches are used, such as mutagenesis to limit
the amount of accessible, reactive amino acids, or the use of
enzymes to enhance the regioselectivity of the conjugation
reaction. In addition, unnatural functionalities can be introduced
into proteins and peptides. Because this introduces a bigger pallet
of potential chemical transformations, it is possible to establish
bio-orthogonal coupling methodologies that tolerate a diverse
array of natural functionalities. A less used method is to couple
the protein and polymer via non-covalent interactions using, for
example, natural cofactors.
1.2 Architecture
The architecture of the bioconjugate has to be adjusted to the
application for which it is developed. The most common
architecture is the head-to-tail conjugate (Fig. 1A). This
set-up can be described as a linear AB block copolymer where
the polymer serves as one block and the protein or peptide as
the other. This architecture is often used for conjugates where
polymers act as protective shields around the biomolecule.
Alternatively, one can imagine a comb-shaped structure with
peptides or proteins installed as side chain groups on a
polymer backbone (Fig. 1B). The high loading capacity of
this architecture makes it an interesting drug delivery system.
It can furthermore be a favourable architecture in cases where
the bioactivity is related to having multiple copies of a peptide
in close proximity of each other. The density of the bio-
molecules can be increased even further by using dendrimers
as the support structures (Fig. 1C).
1.3 Strategies
This review will be structured around the three diﬀerent
strategies used for the synthesis of polypeptide–polymer
bioconjugates.
The grafting to strategy is the most well-established and
involves the coupling of a preformed polymer with a protein or
peptide. Because this strategy tries to bring two macro-
molecules together, the coupling reaction has to be very
eﬃcient. This demanding coupling can sometimes be aided
by an indirect functionalization. In this context, the protein is
not reacted directly with a polymer, but is rather linked to a
heterofunctional spacer ﬁrst. In this way, a more reactive
secondary functionality is introduced into the protein, which
alleviates problems associated with the lack of reactivity when
bringing two large molecules together.
The grafting from strategy is based on a polymer chain
propagating (growing) from a protein or peptide surface. In
this set-up, the protein or peptide acts as a macroinitiator.
Consequently, an initiating moiety needs to be introduced into
the biological molecule. This method has only become practical
since the advance of controlled radical polymerization (CRP)9
techniques, which tolerate a wide variety of functional groups
within the reaction mixture and can be performed under
benign conditions. Alternatively, a peptide can be grown from
a preformed synthetic polymer serving as the macroinitiator.
Finally, the grafting through strategy involves the polymeriza-
tion of peptide-functionalized (macro)monomers. Peptides are
functionalized with a polymerizable group, which serves as a
handle to string the monomeric units together, thus resulting in a
comb-shaped structure with a high density of peptides.
When compared to grafting to, grafting from and grafting
through have the potential to facilitate an eﬃcient synthesis of
Fig. 1 Cartoon representation of the most common architectures of
bioconjugates. The curved lines represent the synthetic polymer
component and the ellipses the peptide or protein: (A) head-to-tail
conjugate, (B) comb-shaped structure, (C) dendritic architecture.
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bioconjugates, because at ﬁrst, only a small component needs
to be coupled to the protein or peptide, after which the
polymer component is grown in a stepwise fashion.
2. Grafting to using natural functionalities
2.1 Amine conjugation
The ﬁrst-generation methods that were developed to create
protein polymer hybrids under mild chemical conditions were
based on reactions between the activated hydroxyl group of
poly(ethylene glycol) (PEG) chains and primary amines from
proteins.10 The latter groups are abundantly present on the
surface of proteins in both lysine residues and the N-terminus.
This facilitates easy functionalization by both alkylation,
which maintains the positive charge of the protein at physio-
logical pH, and acylation, which is accompanied by loss of
charge at the conjugation site.
Generally speaking, these ﬁrst-generation methods are non-
speciﬁc and result in the attachment of polymers at multiple
sites on the protein. Nevertheless, this type of modiﬁcation,
also known as PEGylation, has been widely employed since
the 70s to reduce the limitations of protein-based drugs, such
as a short half-life and immunogenicity.3–5 PEGylation leads
to an increased water solubility11 and stability,12 prevents
clearance through the kidneys, and hence gives rise to a
prolonged plasma lifetime.13 In one of the ﬁrst examples,
Abuchowski et al. showed that the covalent attachment of
PEG chains to bovine liver catalase reduced the immunogenicity
of this protein.14 Moreover, PEGylated catalase was shown to
exhibit prolonged circulating times in the blood of mice. Since
then, many diﬀerent proteins have been modiﬁed such as
hormones,11 antibodies15 and cytokines.16 Ultimately, these
eﬀorts have led to protein–polymer hybrid products on the
market, of which PEG–bovine adenosine deaminase
(ADAGEN) was the ﬁrst to obtain FDA approval in
1990.3,17 Although PEGylation has been demonstrated to be
an eﬀective method of enhancing protein properties, one of the
limitations is the accumulation of PEG in the liver, especially
if high molecular weight PEG chains are employed.13
The oldest PEGylation method uses cyanuric chloride.14,18
Originally, cyanuric chloride was used in industrial applications
to covalently couple dye molecules to fabrics. After being
coupled to PEG, the second chloride of the PEG dichlorotriazine
derivative (1) can easily react with amines from a protein at
room temperature and at pH 9 to form a secondary amine
linkage (2) (Scheme 1).10 A drawback of dichlorotriazine-
activated PEG, however, is that it can react with other
nucleophilic residues, such as cysteine, serine, tyrosine and
histidine. Moreover, the third chloride, while less reactive, can
still partially react with nucleophilic groups, which can result
in crosslink formation. A way around this problem is to
decorate cyanuric chloride with two PEG chains before
conjugation, leaving only one chloride on the triazine ring
available for coupling with the protein.19 A ﬁnal important
consideration for in vivo applications is still the potential
toxicity of cyanuric chloride and its derivatives.
Another reagent that was designed to couple proteins to
polymers via a secondary amine is tresylate (3) (Scheme 1).20
PEG tresylate has the advantage over PEG dichlorotriazine
that it has a higher speciﬁcity towards amines. However, it was
shown that during the conjugation with small amines, PEG
tresylate does not always simply react by the familiar C–O
cleavage process associated with sulfonic esters (4).
Scheme 1 First-generation conjugation methods, which use activated hydroxyl groups for the functionalization of primary amines from peptides
and proteins via alkylation and acylation.
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Conjugation can also occur through a sulfoacetamide linkage
(5).21,22 Because the resulting sulfoacetamide linkage is more
susceptible to hydrolysis, the formation of such a hetero-
geneous mixture can hamper the applicability of this method.
Reacting the hydroxyl end-group of PEG with epichloro-
hydrin allows a terminal epoxy moiety to be introduced
(Scheme 1). The epoxy-functionalized PEG (6) can subsequently
be employed to modify the polymer chain with a protein by
amine bond formation (7).23
Another widely used method for the activation of PEG
towards amines uses N-hydroxysuccinimide (NHS) esters
(Scheme 1). The NHS ester can be introduced into a PEG
polymer chain by coupling it to the carboxylic acid of
succinylated PEG.24 The succinimidyl succinate PEG (8)
which is formed is highly reactive towards amines at physio-
logical pH and forms amide bonds with proteins (9). The
major drawback of this method is the potential hydrolysis of
the ester bond of succinylated PEG. A way to avoid this
problem is coupling of NHS to the PEG chain via a carbonate
group (10).25,26 The carbamate bond that is formed after
conjugation with a protein (11) is very stable against hydrolytic
cleavage. Interestingly, the reactivity of the NHS ester appears
to decrease when the distance between the activated ester and
the PEG backbone is increased. This was illustrated when the
spacer molecule was extended from a propionic acid to a
butanoic acid.27 The reactivity was further decreased by
introducing an a-branching methyl group into the spacer.
This diﬀerence in reactivity was attributed to the steric
hindrance of the extra branching moiety, demonstrating the
subtlety of this coupling process.
In the abovementioned cases, the NHS group was
introduced into the polymer chain in a post-polymerization
modiﬁcation process. In order to avoid possible problems that
can arise from this approach, such as incomplete modiﬁcation,
NHS-functionalized initiators (17 and 18) have been employed
to build up a functional polymer chain (Scheme 2). This
approach was shown to be successful for the synthesis of
polymethacrylates using Atom Transfer Radical Polymerization
(ATRP).28,29 In accordance with the decreased reactivity of the
propionic- and butanoic-based NHS ester after introducing
a branching moiety,27 it was also found that when the
NHS-functionalized initiator 17 was replaced by initiator 18,
the resulting polymer was unable to couple to the protein.
Other activated esters that have been used to couple
polymers to proteins via acylation include p-nitrophenyl carbonate
(12),30 trichlorophenyl carbonate (13),30 imidazole carbamate
(14),31 pentaﬂuorophenyl ester (15, R = F)32 and its more
water soluble counterpart 4-sulfo-2,3,5,6-tetraﬂuorophenyl
ester (15, R = SO3Na)
33 (Scheme 1). All these derivatives
are less reactive than the above mentioned succinimidyl
carbonate. Generally speaking, however, a lower activity of
the coupling moiety will result in a higher selectivity towards a
speciﬁc amino acid residue within the protein.
Until now, we have seen strategies where polymers are ﬁrst
functionalized with a reactive group and then coupled to a
peptide in a separate step. Instead, conjugation can also be
accomplished directly by activating the polymer in situ with
the use of a carbodiimide.34 In this manner, the carboxylic
group of succinylated PEG24 was activated and coupled to
various peptides.35 When using organic solvents, N,N0-diiso-
propyl carbodiimide (19, DIC) is the coupling reactant of
choice. The water-soluble 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide hydrochloride (20, EDC) is suitable for reactions
in the aqueous phase (Scheme 3).
A drawback of PEGylation, and of bioconjugation
with polymers in general, is the polydisperse nature of the
polymeric part of the conjugates, which could lead to populations
of structures with diﬀerent biological properties. This can of
course be circumvented by making use of monodisperse
polymers, as has been elegantly demonstrated by Kochendoerfer
et al.36 A second, more prominent, limitation arises from the
heterogeneous nature of the bioconjugates synthesized with
the abovementioned ﬁrst-generation PEGylation methods.
Because the attachment of the PEG chains using these
methods is non-speciﬁc, products generally suﬀer from a
severe loss in bioactivity, ranging from 20% to 95%.37 This
illustrates the requirement and importance of site-selective
conjugation methods. Possibilities to gain the needed control
over the macromolecular architecture of the bioconjugates will
be discussed in the next sections.
2.1.1 Active site blocking during conjugation. One possibility
to get better selectivity over the synthesis of the bioconjugates
is to shield the active site of the enzyme or the recognition area
of the protein during the coupling reaction (Fig. 2). To achieve
this, an inhibitor, a substrate or a ligand can be used to cover
the reactive groups in the sensitive areas. This strategy was
ﬁrst illustrated by Veronese et al. by protecting the enzyme
trypsin with benzamidine during conjugation with an NHS-
activated PEG chain.38 This led to higher hydrolytic activity
compared to derivatives obtained without any protection. In a
related example,39 avidin was PEGylated in the presence of a
biotin–PEG conjugate as a protective agent. Shielding of
avidin’s biotin binding site proved eﬀective during conjugation
of large PEG chains (10 and 20 kDa). However, in the case of
smaller PEG chains (5 kDa) this protection strategy had no
positive eﬀect on the aﬃnity of the resulting avidin conjugate.
2.1.2 Mutagenesis.A secondmethod to increase the selectivity
of the above described ﬁrst-generation conjugation reactions is
to limit the availability of the reactive groups in the protein by
replacing reactive amino acids by non-reactive ones, using
mutagenesis. Following this strategy Yamamoto et al. prepared
a phage library expressing tumor necrosis factor-a (TNF-a)
Scheme 2 NHS-functionalized ATRP initiators.
Scheme 3 Structures of the carbodiimides DIC and EDC.
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in which all lysine residues were replaced by other amino acids.
After screening the library, a TNF-a mutant was isolated,
which was fully bioactive. Since the N-terminus was the only
remaining primary amine, this position could be speciﬁcally
PEGylated using standard succinimidyl chemistry.40–42 A similar
strategy was successfully employed for the conjugation of
epidermal growth factor (EGF) to PEGylated liposomes.43
However, removing lysines from a protein structure can be a
risky strategy. When adapting this approach to interferon-b-1b
(IFN-b-1b), the biological function of the protein was
completely lost.16 In such instances, other ways for increasing
the speciﬁcity of the conjugation reaction have to be explored.
2.1.3 Solid phase. In solid phase peptide synthesis
(SPPS),44 an amino acid is ﬁrst anchored with its C-terminus
to a swollen crosslinked polystyrene resin. In suspension,
sequential deprotection and addition of N-protected amino
acids aﬀords a growing peptide chain in a stepwise fashion.
Cleavage from the resin support ﬁnally aﬀords the ﬁnal
product.44,45 Because the solid support can be puriﬁed from
unreacted substrates and by-products by simple ﬁltration,
coupling reactions can be driven to high conversions by using
large excesses of reagents. Furthermore, as all reactive amino
acid side groups are protected during the synthesis, selectivity
problems are avoided. In this way, the N-terminus of the
synthetic peptide can not only be reacted with an amino acid,
but can also be speciﬁcally coupled with a polymer chain
functionalized with a carboxylic acid or succinimidyl moiety.46,47
After cleavage from the resin and side chain deprotection, the
crude product can be puriﬁed using dialysis or reverse-phase
high-performance liquid chromatography (HPLC). However,
this approach is limited by both the molecular weight of the
polymer that is coupled and the nature of the N-terminal
amino acid.48 Unhindered amino acids such as glycine were
functionalized quantitatively with PEG derivatives, with
molecular weights of up to 5000 g mol1. PEGylation of
hindered amino acids such as isoleucine only proceeded
smoothly with polymers with molar masses below 200 g mol1.
These limitations are due to the reduced end-group reactivity
of larger polymers and their decreased diﬀusion rates into
the crosslinked resin. An interesting example of the SPPS
approach was given by Vandermeulen et al. who were able
to create a series of PEGylated leucine zipper-like peptides of
which the coiled-coil forming ability was enhanced by the
presence of the PEG chains.49
A polymer can also be selectively coupled to the C-terminus
of a peptide by ﬁrst attaching a polymer to the solid support,
followed by the subsequent assembly of the peptide from
the polymer using standard solid phase chemistry.50 This
approach can be seen as a ﬁrst example of the grafting from
strategy, which will be discussed in more detail in section 5.
When a PEG chain is planned as the synthetic component, the
commercially available Tentagel PAP resin can be used. This
resin consists of a polystyrene matrix and a pre-attached PEG
chain with a labile benzyl ether linkage. From this PEG chain,
the peptide can directly be built up as the bioconjugate.51–56
By combining both strategies for the functionalization of the
C- and N-terminus, an ABA triblock was synthesized with two
outer polystyrene blocks.57
Besides modiﬁcation of the peptide termini, amino acid side
chains can also be conjugated with polymers during an SPPS
procedure. Lu and Felix developed two routes for the site-
selective PEGylation of lysine and aspartic acid residues.50 In
the ﬁrst route, the targeted amino acid was ﬁrst coupled to a
PEG chain and then built into the peptide during solid phase
synthesis. In the second route, the peptide was ﬁrst synthesized
on the solid support with Ne-allyloxycarbonyl lysine or b-allyl
aspartate at the conjugation site. These orthogonal protection
groups were removed selectively, after which the peptide was
site-selectively PEGylated, while still on the resin.
Mutter et al. used the concepts from SPPS and transformed
them into a liquid-phase procedure.58 Peptides were assembled
on a linear PEG support in a homogeneous solution. After
each step, excess reagents and by-products were removed by
membrane dialysis or precipitation of the growing peptide in
diethyl ether. The advantage of this method is that inter-
mediate products can be analyzed using standard techniques
such as NMR. The method has, however, never found wide-
spread application in the synthesis of peptide polymer
conjugates, possibly because it can be diﬃcult to ﬁnd the
optimal synthetic conditions.
2.1.4 Reductive alkylation. As the e-amine group on lysine
and the primary amine at the N-terminus have diﬀerent pKa’s,
(about 10.0–10.2 and 7.6–8.0, respectively),59 their diﬀerence
in reactivity under slightly acidic conditions can, in principle,
be utilized for the selective functionalization of the N-terminus
with the previously mentioned activated esters. In practice,
however, this is very diﬃcult because of the reactive nature of
these esters and only a few successful examples are known.60,61
An alternative for achieving speciﬁc conjugation is changing
the chemistry used. One possibility is to introduce an aldehyde
on the polymer chain (21),62 which can be coupled to an amine
and form a Schiﬀ base (22). This intermediate is reduced in the
presence of sodium cyanoborohydride to a stable secondary
amine (23) (Scheme 4).11,63–66 Using this reductive alkylation
method, selective functionalization of the N-terminal amine
group is possible12,16,67,68 while leaving the lysine side chain
amines untouched.
Reductive alkylation proves to be quite eﬃcient. When
comparing immobilization methods for human serum
albumin (HSA) to monoliths composed from methacrylate-
based polymers,69 the reductive alkylation protocol resulted
in a more eﬃcient immobilization than the epoxy,23
Fig. 2 Active site blocking during bioconjugation. An inhibitor,
substrate or ligand is added during the conjugation step, thereby
shielding the reactive groups in the sensitive area (marked with a
cross).
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succinimidyl carbonate25,26 and carbodiimide34 methods.
These columns were subsequently used to separate both
racemic warfarin and tryptophan, where the column prepared
by reductive alkylation was found to give the best resolution.
However, reductive alkylation has as a drawback the use of
sodium cyanoborohydride, which is both water-sensitive and
has the potential for reducing disulﬁde bonds within proteins.
A variation of this method avoids these problems by using a
water-stable iridium catalyst for the reduction.70 However,
this method is not as eﬃcient as the classical reduction and no
selectivity for the N-terminal amine has been shown yet.
Another variation of the reductive alkylation procedure used
an acetal moiety, which was converted to an aldehyde in situ
before coupling. By storing the aldehyde functional polymer as
its corresponding acetal derivative, a longer shelf life was
guaranteed. The acetal moiety was either coupled to a
pre-existing polymer71 or built into a polymer by synthesizing
the polymer with an acetal-functional initiator.72 A similar
chemical approach for surface immobilization was followed by
Christman et al., who elegantly decorated a methacrylate
surface with streptavidin by making use of an acetal-protected
aldehyde functionality that can be deprotected by irradiation.73
Using this methodology together with photomasks, patterns
were obtained with features as small as 500 nm.
2.2 Cysteine conjugation
The frequent occurrence of lysines on protein surfaces makes it
hard to site-selectively target the amine groups of these
residues. As mentioned above, reductive alkylation can target
theN-terminus selectively, and active site blocking, mutagenesis
and solid phase synthesis can be used to limit the amount of
available lysines on the protein or peptide.
Another, easier way to create well-deﬁned polypeptide–
polymer bioconjugates is to target a more speciﬁc functionality
within the peptide or protein. In polypeptides there are only a
few cysteines that do not participate in disulﬁde bonds. This
low natural abundance makes it easier to functionalize
proteins via the available cysteines at a speciﬁc location and
thus minimize loss of biological activity. As an additional
advantage, the overall charge of the polypeptide is maintained.
In the absence of a free and accessible cysteine in the native
structure, one can be added by site-directed mutagenesis74,75
or by introducing a cysteine-containing peptide connector in a
fusion-protein.76 However, these strategies can be dangerous,
as the addition of a single cysteine increases the possibility of
incorrect disulﬁde formation and protein dimerization.
Generally speaking, conjugations that target cysteines can
be divided into thioether- and disulﬁde-forming reactions,
which will be discussed in the next sections.
2.2.1 Thioether formation. One of the cysteine reactive
reagents that reacts with thiols via a Michael addition is the
alkylating agent vinyl sulfone (24) (Scheme 5). Because of the
soft nature of this electrophile, it is quite selective to thiols,
even in the presence of other hard nucleophiles such as amines
and hydroxyl groups. However, the vinyl sulfone group only
reacts slowly with thiols. The reaction is accelerated by
increasing the pH, but this will also give more side reactions
with lysines. The charge environment of the cysteine can
furthermore also have an eﬀect on the ease of the reaction.77
In one example of this strategy, chloroethyl sulfone was ﬁrst
introduced to a PEG chain by a four-step procedure, and then
converted to vinyl sulfone in the presence of base.78 This gave
the possibility to selectively attach the PEG derivative to the
cysteine residues of reduced ribonuclease (RNase). In the
area of tissue engineering, a,o-divinyl sulfone PEG chains
were crosslinked into hybrid hydrogel networks with
protein–polymer-containing cell-binding sites.79 In another
example, this method was furthermore used for the
immobilization of the RGD protein on a surface.80
In another example of the application of cysteine conjugation
using vinyl sulfone chemistry, polymers were prepared by
polymerization of N-isopropylacrylamide (26, NIPAAm) via
chain transfer free radical polymerization. The resulting
polyNIPAAm is thermo-responsive due to its lower critical
solution temperature (LCST). Above this critical temperature,
water is expelled, turning the polymer into an insoluble
hydrophobic state. The terminal hydroxyl group of
polyNIPAAm was modiﬁed with divinyl sulfone, and the
resulting thiol-reactive polymer was subsequently conjugated
speciﬁcally to an unnaturally occurring cysteine in both
streptavidin81–85 and endoglucanase 12A86,87 mutants.
Likewise, copolymers of N,N-dimethyl acrylamide (27, DMA)
and two diﬀerent light-sensitive co-monomers, 4-phenyl-
azophenyl acrylate (28, AZAA) and N-4-phenylazophenyl
acrylamide (29, AZAAm), were attached to streptavidin using
the vinyl sulfone moiety.82,83 Conjugation of these thermal- and
light-sensitive polymers to proteins results in stimuli-responsive
materials of which the thermal- and photo-induced changes
are used to regulate substrate access to the protein’s active
site. Such switchable systems might ultimately be employed in
Scheme 4 Mechanism of the reductive alkylation.
Scheme 5 Cysteine conjugation using vinyl sulfone, together with
some examples of the polymers employed.
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diagnostic assays and demonstrate the possibilities of
speciﬁc conjugation methods that can introduce polymer chain
close to the active site, without destroying the protein’s
activity. These protein–polymer bioconjugates are commonly
referred to as ‘smart’ materials, and besides light and
temperature, examples are also known where their properties
alter upon changes in pH and ionic strength.7
A more widely used Michael acceptor is the maleimide
group (30) (Scheme 6). It reacts faster than vinyl sulfone and
the conjugation can also be performed in slightly acidic
conditions (pH 6–7). However, the resulting product (31) is
less stable in water. The maleimide group can be intro-
duced in various ways, for instance by ﬁrst reacting an
amine-terminated PEG (32) with maleic anhydride (33),
followed by dehydratation and ring-closure of the intermediate
maleamic acid by acetic anhydride and sodium acetate.88
In an alternative procedure, a-amino polyNIPAAm (35) was
ﬁrst coupled to an N-hydroxysuccinimide (NHS) activated
maleimide (36) and then conjugated to a cysteine, which was
introduced into cytochrome b5 by site-directed mutagenesis of
a surface accessible threonine.89 The same strategy was used to
conjugate the multi-subunit DNA restriction-modiﬁcation
enzyme EcoR124I endonuclease (REase) to a-functional
maleimide polyNIPAAm.90
An a-maleimide functional polymer can also be synthesized
by performing an ATRP polymerization with a maleimide
functional initiator. However, before polymerization, the
maleimide initiator needs to be protected, for instance via a
Diels–Alder reaction with dimethylfulvene (38)91 or furan (39)
(Scheme 7).92 After polymerization, the protecting group can
be liberated by reﬂuxing the polymer at elevated temperature.
In one example of the maleimide-based coupling, the
terminal carboxylic acid of polystyrene was converted into
an acid chloride and reacted with maleimide under basic
conditions.93 The single disulﬁde bond of Candida antarctica
lipase B (Cal B) was reduced and the conjugation to the free
cysteines was carried out in a mixture of tetrahydrofuran and
water or on the air–water interface. This conjugation was
employed to induce self-assembly of the protein and these
structures have been coined as giant amphiphiles by the Nolte
group.93 It was found that in aqueous media these amphiphilic
structures form a variety of aggregates. Unfortunately, the
aggregate formation is often accompanied by a severe loss in
activity of the enzymes involved. A similar conjugation
approach was used for the immobilization of a Cal B mutant
onto a glass surface in which one cysteine of the disulﬁde
bridge was mutated to an alanine.94 In a separate report,
polyamine dendrimers with a maleimide-functionalized core
were conjugated to the single cysteine of Bovine Serum
Albumin (BSA) or a genetically engineered cysteine mutant
of Class II hydrophobin (HFBI).95
On the other hand, it was proven possible to conjugate PEG
to a cysteine buried inside a hydrophobic pocket of HSA using
a two-step procedure.96 First, a glycoside bearing a dodecyl
tail was functionalized with an NHS-activated maleimide. This
hydrophobic spacer was used to facilitate conjugation to the
buried cysteine. In a second step, the sugars were selectively
oxidized using sodium m-periodate and the thus introduced
aldehydes were coupled to PEG–hydrazine (see section 3.3 for
hydrazone ligation). This two-step procedure was far more
eﬀective than direct conjugation of maleimide–PEG.
An alternative procedure, which is gaining interest, uses the
century-old addition of thiols to alkenes through a photo-
chemically or thermally induced radical mechanism (Scheme 8).97
This thiol–ene coupling (TEC) is bioorthogonal, eﬃcient,
and compatible with water and oxygen. Its potential for
bioconjugation was ﬁrst demonstrated by the conjugation of
1,2-polybutadiene (PBD) and PBD-b-PEG to short model
peptides, resulting in peptide hybrid amphiphiles.98,99 More
recently, this method has been used to pattern surfaces with
proteins.100 To this end, polyamidoamine (PAMAM) dendrimers
were ﬁrst covalently coupled to a silicon oxide surface.
Coupling of an aminocaproic acid spacer to the dendrimers,
followed by functionalization with cystamine and subsequent
reduction, resulted in the immobilization of the thiol-
functionalized dendrimers on the surface. Treatment of the
surface-bound thiol groups with alkene-functionalized biotin
combined with irradiation through a photomask in the
Scheme 6 Use and synthesis of maleimide-functionalized polymers.
Scheme 7 Maleimide-functionalized ATRP initiators.
Scheme 8 Mechanism of the thiol–ene coupling.
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presence of a photoinitiator, led to a spatially selective coupling
of biotin via thioester bond formation. Subsequent incubation
with streptavidin ﬁnally produced a protein-patterned surface.
In a separate report, the selective functionalization of a
heterotelechelic polystyrene (PS) with both an alkene and an
azide end-group furthermore demonstrated the orthogonality
of the TEC with the copper-catalyzed azide–alkyne
Huisgen 1,3-dipolar cycloaddition, which will be discussed in
section 3.1.101
2.2.2 Disulﬁde formation. Another strategy for the conjugation
to cysteines involves the formation of disulﬁde bonds. To this
end, the thiol group of the cysteine residue on the peptide is
reacted with an activated disulﬁde group on a polymer. A
thiol–disulﬁde exchange subsequently forms a new disulﬁde
bond connecting the peptide with the polymer. An advantage
of this strategy is that the activated disulﬁde group reacts
speciﬁcally with thiols under a broad pH range (pH 3–10). The
disulﬁde bond formation is completely reversible and can be
reduced using standard reducing agents like dithiothreitol
(DTT). Depending on the application, this can be regarded
as either an advantage or disadvantage.
The most widely used activated disulﬁde is o-pyridyl
disulﬁde (44) (Scheme 9). It reacts very eﬃciently towards
the end product, because the o-pyridyl disulﬁde group is
expelled from the substrate as a nonreactive compound (46),
which can no longer participate in the thiol–disulﬁde exchange
reaction. In line with this strategy, PEG was ﬁrst functionalized
using an NHS-activated o-pyridyl disulﬁde and then conjugated
to mutagenically introduced cysteines on Pseudomonas
Exotoxin A (PE).102 Alternatively, o-pyridyl disulﬁde was
introduced to PEG by activating the terminal hydroxyl groups
with p-nitrophenyl chloroformate, followed by coupling of
2-(2-pyridyldithio)ethylamine.103 These postpolymerization
modiﬁcations can be circumvented by using pyridyl
disulﬁde-functionalized initiators, which have been used
successfully in the ATRP polymerization of 2-hydroxyethyl
methacrylate (HEMA).104
In a demonstration of the usefulness of this conjugation
chemistry, the heptameric protein pore a-hemolysin (aHL)
was selectively PEGylated with a single polymer chain in its
lumen.105 For its construction, single-cysteine aHL mutants
were conjugated with an o-pyridyl disulﬁde PEG chain and
then mixed with unmodiﬁed aHL unimers. After self-assembly
of the heptamer, the desired product could be isolated. In
another example, a-(o-pyridyl disulﬁde)-o-(hydroxysuccinimide)
PEG was ﬁrst coupled to amine-functionalized atomic force
microscopy (AFM) tips. In a second step, thiolated antibodies
were conjugated to the cysteine-reactive end of the hetero-
telechelic PEG. The thus immobilized antibodies were then
tested in single-molecule recognition experiments.106 Instead
of only using the terminal end-group of a polymer for the
immobilization of an antibody, side chain functionalization
can be used to give high loading densities. With this idea in
mind, polymer brushes of 2-methacryloyloxyethyl phosphoryl-
choline (MPC) and glycidyl methacrylate (GMA) were grown
using ATRP.107,108 Using the epoxy groups of the GMA
residues, o-pyridyl disulﬁde was introduced in the side chain
of the polymer brush and used to immobilize antibody
fragments.
Alternatives for the o-pyridyl disulﬁde activating group are
the p-pyridyl disulﬁde,109 alkoxycarbonyl or o-nitrophenyl
groups.110 The ﬁrst activating group was used for the
conjugation to the model protein papain and the last two
showed good reactivity towards the tripeptide glutathione.
2.2.3 Bridged disulﬁde bond. As previously stated, it is very
rare to have naturally occurring unpaired cysteines on the
surface of proteins. Cysteines in disulﬁde bridges are more
common; however, most of them are buried and only few are
accessible on the surface of peptides. A newly developed
strategy for the site-selective modiﬁcation of peptides targets
these disulﬁde bridges (Scheme 10).111 Under mild reducing
conditions and without the use of denaturants, it was possible
to selectively reduce the surface-accessible disulﬁde bridges
only. The two liberated thiols were treated with a bis-alkylating
PEGylation agent (47).
The addition of the ﬁrst thiol (48) resulted in the elimination
of a sulﬁnic acid derivative. The conjugated double bond that
was formed (49) provided the addition site for the second
thiol. With this method, PEG was conjugated via a three-
carbon bridge that links the two original sulfur atoms (50).
The sequential nature of the addition–elimination reactions
ensures the eﬃcient rebridging of the original disulﬁde bond,
stabilizing the correct tertiary structure of the peptide. This
strategy has been shown for the selective functionalization of
interferon a-2, leptin, asparaginase and antibody fragments.112
2.3 Tyrosine conjugation
As a complement to the use of cysteines and lysines, tyrosine
oﬀers another possible conjugation site on proteins and
peptides. An added advantage of tyrosine is that it can be
introduced or removed genetically without changing the total
charge of a protein (as with lysine) or its redox sensitivity
(as with cysteine).
It is known that tyrosines can react with diazonium salts
(Scheme 11). In line with this method, poly(vinyl alcohol) was
crosslinked into water-insoluble beads and then diazotized.113
Using these diazonium-functionalized beads (51), BSA and
b-glucosidase were immobilized. However, it was noted that
the diazonium moiety can also react with the electron-rich
aromatic systems of the histidine side chain, which could result
in uncontrolled side reactions.
Francis et al. developed two tyrosine conjugation methods
that are more selective and could prove very useful in the
synthesis of protein–polymer hybrids. The ﬁrst one is based on
a three-component Mannich-type reaction between tyrosine
(52), an aliphatic aldehyde (54) and an aniline-derivatized
ﬂuorescent probe (55) (Scheme 12).114 This method was used
to label chymotrypsinogen A, lysozyme and RNase A.
However, this method requires a large excess of the aldehyde
and aniline. Therefore, a second method was introduced,
which only requires a small excess of the synthetic partners.115Scheme 9 Thiol–disulﬁde exchange with o-pyridyl disulﬁde.
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There, an inert allylic acetate (57) was ﬁrst activated by a
palladium catalyst. The electrophilic p-allyl complex (58) was
subsequently coupled to the tyrosine of chymotrypsinogen A
(52), introducing either a ﬂuorescent probe or hydrophobic
tails on the protein (59).
2.4 Native chemical ligation
Native chemical ligation (NCL) is based on a mechanism
known from nature, which involves intein-associated protein
splicing.116 It was ﬁrst adopted in the preparation of synthetic
peptides as a convenient technique that enables chemoselective
coupling of two unprotected peptide segments.117 In the
ﬁrst step of the reaction, a peptide fragment with a C-terminal
a-thioester (60) reacts with another polypeptide with an
N-terminal cysteine (61). Initially, a thioester-linked species
(62) is formed, which spontaneously rearranges via an intra-
molecular reaction to form a native peptide bond at the
ligation site (63) (Scheme 13). This reaction proceeds with
high yields at neutral pH. The requirement to have a cysteine
at the ligation site limits the applicability of NCL, as cysteines
are relatively rare amino acids in natural proteins. Several
approaches, however, have recently been described that
circumvent the use of cysteines.118,119
NCL was ﬁrst applied by Merkx and Meijer et al. as a
bioconjugation tool for attaching oligopeptides and recombinant
proteins to dendrimers.120,121 Hyperbranched polymers
obtained from poly(propyleneimine) were reacted with
succinimide-activated cysteine residues. This aﬀorded dendrimers
of the ﬁrst, second and third generation with 4, 8 and 16 cysteine
end-groups, respectively. Ligation reactions were performed
with three oligopeptides (Leu–Tyr–Arg–Ala–Gly, Gly–Arg–
Gly–Asp–Ser–Gly–Gly and Lys–Leu–Val–Phe–Phe–Gly–Gly)
bearing mercaptopropionic acid–leucine (MPAL) thioesters at
their C-terminus. For dendrimers of generations one and two,
full conversion was observed. For the third-generation den-
drimers, a mixture of products was found, probably due to
steric crowding. After having shown the viability of this
methodology for the coupling of peptides, it was extended
for proteins by coupling green ﬂuorescent protein (GFP) to a
ﬁrst-generation dendrimer. GFP was ﬁrst expressed as an
Scheme 10 Mechanism of disulﬁde bridge formation using a bis-alkylating PEGylation agent.
Scheme 11 Reaction between tyrosines and a diazonium functiona-
lized bead.
Scheme 12 (A) Three component Mannich-type tyrosine conjuga-
tion; (B) palladium-assisted tyrosine conjugation. Scheme 13 Mechanism of the native chemical ligation.
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intein fusion protein (Scheme 14). Binding of this fusion
protein on a resin (64) was followed by a nucleophilic attack
with sodium 2-mercaptoethanesulfonate (MESNA) (66),
which reacted with the transient thioester (65) at the intein
fusion site. After coupling this GFP-based MESNA thioester
(67) to the dendrimer, the remaining cysteines were further
functionalized with peptide-based MPAL thioesters. A similar
strategy was followed to immobilize peptides and proteins to a
cysteine-functionalized dextran surface.122
NCL was also used for the ligation of two nonsymmetric
poly(lysine) dendritic wedges.123 One dendritic wedge
with four cysteine residues along its periphery was ﬁrst
functionalized by NCL using the thioester-containing peptide
Gly–Arg–Gly–Asp–Ser–Gly–Gly–MPAL, which can bind
anb3 integrins. Then, the thioproline residue at the focal point
of the dendritic wedge was converted to a cysteine residue
by reacting it with methoxylamine. The second dendritic
poly(lysine) wedge with sulfhydryl groups at its periphery
was coupled to maleimide-functionalized diethylenetriamine
pentaacetic acid (DTPA), a labeling agent in magnetic
resonance imaging (MRI). The thioester at the focal point of
this wedge could then be used in a native chemical ligation
with the ﬁrst peptide-functionalized wedge.
Becker et al. used discrete PEG-based oligomers carrying
thioester moieties for the functionalization of an array of
peptides and proteins using NCL.124 Here, it was shown that
this procedure leads to the reversible attachment of polymer
chains to any internal cysteine residues via thioester bonds.
N-terminal cysteines on the other hand, are permanently
modiﬁed through amide bond formation as shown in
Scheme 13. This diﬀerence in bond formation between internal
and N-terminal cysteines eﬀectively allowed Rab GTPase,
which contains three cysteines, to be selectively functionalized
at the N-terminus.
2.5 Site-selective modiﬁcation using enzymes
Site-selective PEGylation of proteins can be accomplished by
using enzymes in the conjugation step. The ﬁrst example of
this biosynthetic approach used the enzyme transglutaminase
(TGase).125 In its natural environment, TGase catalyses the
post-translational modiﬁcation of proteins by alkylating the
amine group of glutamine with a primary alkylamine
(Scheme 15).126
Mammalian TGase has a stringent sequence requirement
for the amine acceptor site around the glutamine residue.
Therefore, in order to conjugate amine-functionalized PEG
to the human protein interleukin-2 (hIL-2) using mammalian
TGase, a short substrate sequence had to be cloned onto the
N-terminus of hIL-2. The chimeric protein could be selectively
functionalized at the appended substrate sequence and
retained most of its bioactivity, while showing prolonged
circulation in rat plasma. Alternatively, microbial TGase can
be used for the conjugation reaction. This enzyme recognizes a
wider variety of protein substrates as an amine acceptor. This
allowed for one glutamine residue in native hIL-2 to be
identiﬁed as a substrate for the microbial TGase. The other
ﬁve glutamines in the hIL-2 sequence were left untouched and
the well-deﬁned bioconjugate that was formed retained its
full bioactivity and possessed improved pharmacokinetics.
Recently an excellent review was published covering the ﬁeld
of PEGylation mediated by transglutaminase.127 In another
application of the enzyme, GFP and glutathione-S-transferase
were immobilized on a surface using TGase.128 Both proteins
were tagged with a glutamine-containing substrate sequence at
their C-terminus and coupled to a b-casein coated surface,
possessing reactive lysine residues.
For the site-speciﬁc conjugation of serine and threonine
residues, a diﬀerent enzyme has been used.129 In one example,
three therapeutic human glycoproteins were expressed in
Escherichia coli (E. coli) in their nonglycosylated form and
PEGylated in a two-step procedure. First, their natural
O-glycosylation site was functionalized with the sugar
N-acetylgalactosamine (GalNac) using GalNac transferase.
Subsequently, sialic acid-functionalized PEG was enzymatically
coupled to the GalNac residue by sialyltransferase. The process
provided a biologically active, chemically homogeneous
bioconjugate with extended plasma half-life.
Another interesting pathway130 that is inspired by the
natural selectivity of enzymes takes advantage of the ability
of O6-alkylguanine-DNA alkyltransferase (AGT) to transfer
the benzyl group of O6-benzylguanine (BG) to one of its
cysteine residues.131 Originally, AGT was used in biochemistry
for the labeling of proteins. To this end, the protein of interest
is fused to an AGT tag and subsequently coupled covalently
to a BG-functionalized ﬂuorescent probe. Similarly, an
Scheme 14 Functionalization of the N-terminus of GFP with
MESNA (66) using an intein fusion protein.
Scheme 15 TGase is activated by Ca2+. In this conformation, thiol
residue (69) is coupled to the glutamine side chain of its substrate (68).
Transamidation of the intermediate structure 70 releases the alkylated
product (71).
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AGT-fusion protein can react with a polymer in order to
create a bioconjugate. This strategy was illustrated by reacting
an AGT-fusion protein speciﬁcally with BG-functionalized
polymer brushes, thereby immobilizing the fusion protein to
the surface. Because the bioconjugation occurred exclusively
via the reaction of the AGT tag, immobilization could be
carried out directly from the crude cell lysates without the need
for separate puriﬁcation steps. The mild procedure left the
fusion protein intact and free to react with its substrate.
Furthermore, the density of protein on the surface was varied
by changing the amount of BG that was anchored to the
brush. Currently, three other tags are used for covalent
labeling of proteins inside living cells: the CLIP tag,132 the
tetracysteine tag133 and the HaloTag.134 One could envision
that these tags could also be employed for bioconjugation
using the same strategy.
3. Grafting to using unnatural functionalities
Peptides and proteins are both rich in structural complexity
and diverse in their functional reactivity. We have seen that the
high number of electrophilic and nucleophilic sites can make it
diﬃcult to selectively couple peptides and proteins to polymers
using naturally occurring functional groups. Therefore,
chemoselective ligation reactions have been developed in
which two mutually and uniquely reactive functional groups
react with one another. The chosen reactive groups are bio-
orthogonal, tolerating a diverse array of other functionalities,
and thus render protecting groups unnecessary. Because of
their robust nature, these reactions are commonly grouped
under the name ‘click’ reactions.
3.1 Copper-catalyzed azide–alkyne Huisgen 1,3-dipolar
cycloaddition
Thermally induced 1,3-dipolar cycloadditions have been
intensively studied by Huisgen since the 1950s.135 Kolb and
Sharpless,136 and Meldal and Tornoe137 showed that the 1,3-
dipolar cycloaddition between azides (72) and alkynes (73) can
be greatly accelerated by adding a copper catalyst, which
allows the reaction to be performed at room temperature
(Scheme 16).
This copper-catalyzed azide–alkyne Huisgen 1,3-dipolar
cycloaddition (CuAAC) has recently enjoyed tremendous
interest as a synthetic route for the synthesis of complex
materials because of its high conversion and mild experimental
conditions. Azides and alkynes can be easily introduced in
both synthetic polymers and biomolecules. The reaction can
be performed at room temperature and in water, making it
compatible with biological systems. Because this method
involves a cycloaddition rather than a nucleophilic substitution,
proteins can be modiﬁed with extremely high selectivity, so
little or no by-products are formed and no protective groups
are required.
CuAAC was ﬁrst used on proteins for the labeling of protein
capsids of the cowpea mosaic virus (CPMV) with a ﬂuorescent
dye.138 The possibilities of the CuAAC for bioconjugation
with polymers were ﬁrst shown by the site-speciﬁc PEGylation
of human superoxide dismutase-1 (SOD), a key enzyme in
preventing the formation of reactive oxygen species in cells
(Scheme 17).139 The alkyne was introduced into the PEG
polymer by coupling propargylamine with an NHS ester-
activated PEG (75). The azide was incorporated into the
SOD protein (74) by introducing p-azidophenylalanine (77)
as a 21st amino acid (Scheme 18). This was achieved by
extending the repertoire of the cell’s translational machinery
with an orthogonal tRNA and tRNA synthetase.140 This gives
the possibility to site-selectively introduce an azide, while
keeping the rest of the primary structure unchanged. The
CuAAC ligation was performed in a phosphate buﬀer at pH 8,
resulting in a PEGylated SOD (76) that had approximately the
same bioactivity as the native enzyme.
Alternatively, azide groups can be incorporated into recom-
binant proteins by expressing them in methionine-auxotrophic
bacterial cultures growing in methionine-free medium which
are supplemented with azido-homoalanine (78, Scheme 18).141
Because of the close resemblance of azido-homoalanine to
methionine, azido-homoalanine is simply activated by
methionyl-tRNA synthetase and thereby replaces each
methionine in the proteins expressed. Although this means
Scheme 16 (A) Thermally induced cycloaddition between azides and
alkynes; (B) regioselective copper-catalyzed azide–alkyne Huisgen
1,3-dipolar cycloaddition.
Scheme 17 PEGylation of the SOD protein using CuAAc.
Scheme 18 Structures of azide-containing amino acids and diazo
transfer agents.
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that several azido groups can be introduced into the protein,
the low methionine abundance together with its hydrophobicity
will limit the amount of surface accessible azides incorporated.
Accordingly, this strategy was used to site-speciﬁcally PEGylate
the enzyme Cal B.142
Instead of a biochemical approach, the azide group can also
be introduced in a chemical manner into both peptides and
proteins using diazo transfer agents (Scheme 18). Solid phase
bound peptide amines can be easily converted into azides by a
diazo transfer using triﬂyl azide (79) in the presence of divalent
copper ions.143 The water-soluble diazo transfer agent 80144
can be used on proteins in an aqueous solution to substitute
the amines of both lysine residues and the N-terminus by azide
groups.145
In another example of CuAAC bioconjugation, the azide
and alkyne functionalities switched places as an azide-terminated
PS was coupled to either an alkyne-functionalized peptide or
protein.146 The PS block was synthesized by ATRP and the
terminal bromide was subsequently reacted with azidotri-
methylsilane and tetrabutylammonium ﬂuoride (TBAF) to
introduce the azide group. The peptide with the sequence
Gly–Gly–Arg was synthesized by SSPS and ﬂuorescently
labelled. While still on the solid support, the peptide was
reacted with 3-butynylchloroformate, introducing the alkyne
function onto the N-terminus. The subsequent CuAAC was
performed in THF with the same copper catalyst used for the
ATRP synthesis of the PS block. In order to demonstrate the
scope of the reaction, the azide functional PS was also
conjugated to an alkyne-functionalized BSA. Towards this
goal, the available thiol from the cysteine-34 residue of BSA
was ﬁrst coupled to a maleimide bearing an alkyne. The
alkynylated BSA was then reacted with the azide functional
PS using the same reaction conditions as for the synthesis of
the peptide–PS hybrid. Both peptide and protein bioconjugates
displayed amphiphilic properties and their aggregation
behaviour was investigated. In another example, the alcohol
of a-hydroxy-o-methoxy PEG was ﬁrst tosylated and then
substituted by sodium azide.147 The N-terminus of an
oligopeptide was functionalized with pentynoic acid. The
amphiphilic conjugates formed after CuAAC conjugation
self-assembled into nanotubes, which formed soft hydrogels.
In a ﬁnal example, poly(oligo(ethylene glycol) acrylate)
(POEGA) was prepared using ATRP and the terminal bromide
group was replaced with an azide by reacting the polymer with
sodium azide.148 The azido-POEGA was then reacted with the
alkyne functional oligopeptide Gly–Gly–Arg–Gly–Asp–Gly.
In the previous examples, the clickable groups on the
polymer chain were introduced after the polymerization. An
alternative strategy for obtaining clickable polymers is to use
an alkyne or azido functional initiator. Scheme 19 shows some
examples of azide- and alkyne-containing initiators for ATRP
(81, 82),149,150 ring-opening polymerization (ROP) of amino
acid N-carboxyanhydrides (NCA) (83, 84),150 RAFT (85)151
and nitroxide-mediated radical polymerization (86, 87).152 It
has been shown that the azide and (protected) alkyne
functionalities survive the polymerization conditions, eﬀectively
eliminating the need for postpolymerization modiﬁcations.
Besides the construction of linear bioconjugates, CuAAC
has also been employed for the synthesis of polymers with a
brush structure by introducing clickable groups in the monomer
side chain (Scheme 20).153 A polyester with acetylene moieties
was produced by ROP of a-propargyl-d-valerolactone (88).154
Complementary to polyester 89, the amine terminus of a
Gly–Arg–Gly–Asp–Ser oligopeptide sequence was ﬁrst capped
with 6-bromohexanoic acid, after which the bromide was
substituted with an azide. Surprisingly the azide-terminated
pentapeptide 90 could only be coupled to polyester 89 at
100 1C. Another branched structure was produced by coupling
acetylene terminated dendrimers with azide-functional
peptides via CuAAC.155 Because low reaction rates were
observed, Liskamp et al. tried to accelerate the reaction by
microwave irradiation. Varying yields were obtained, ranging
from 14 to 97%, possibly due to steric hindrance.
Scheme 19 Structures of azide- and alkyne-containing initiators.
Scheme 20 Side chain functionalization of a polyester with an
oligopeptide using CuAAC.
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Even more complicated architectures are accessible by
conjugating proteins to self-assembling block copolymers.
An a,o-diacetylene-functionalised PEG was ﬁrst coupled to
an azide-terminated PS via CuAAC to produce a PEG-b-PS
polymer with an acetylene at its hydrophilic extremity. In
water, these amphiphilic structures then assembled into
polymersomes, placing the clickable groups at the surface of
the aggregate. The accessibility of the acetylene was ﬁnally
demonstrated by coupling either azido-functionalised horse-
radish peroxidase (HRP)145 or Cal B.156
In the area of surface immobilization, a heterotelechelic
PEG linker carrying an alkyne and a cyclodiene terminal
group was immobilized onto an N-(e-maleimidocaproyl)
functionalized glass slide via a Diels–Alder reaction.157 This
resulted in an alkyne-terminated PEGylated surface,
which could be used for the conjugation of azide-containing
biomolecules via CuAAC in an aqueous solution.
The abovementioned examples impressively demonstrate
the bio-orthogonality of the CuAAC. However, amino groups
present in peptides and proteins can chelate the copper ions,
thereby interfering with the cycloaddition reaction. Both the
toxicity of the required copper, as well as the copper-induced
denaturation of proteins158 furthermore indicate that this
methodology needs to be improved. To this end, several
copper-free ‘click’ reactions have been developed, which will
be discussed in the next sections.
3.2 Staudinger ligation
In 1919 Staudinger andMeyer reported the reduction of azides
using triphenylphosphine.159 This reaction involves the
formation of an aza-ylide intermediate, which is hydrolyzed
to generate an amine and triphenylphosphine oxide. When
Saxon and Bertozzi incorporated a methoxy ester as an
electrophilic trap into one of the phenyl rings (92), the
nucleophilic aza-ylide 94 was captured before its hydrolysis
(Scheme 21).160Via an intramolecular cyclization, the
intermediate rearranged, and after hydrolysis ultimately
coupled both reaction partners via an amide bond (96). Just
like with the CuAAC, both reactive groups of this Staudinger
ligation (i.e. the azide and the triphenylphosphine) are absent
from peptides and proteins, and although they have a high
intrinsic reactivity to one another, they do not react with any
natural occurring functionalities. This property can be
exploited in the synthesis of well-deﬁned bioconjugates
without the need for protecting groups.
Accordingly, the Staudinger ligation was used for the
site-speciﬁc PEGylation of azido-homoalanine containing
trombomodulin.161 Functionalization of an amine-terminated
PEG with phosphine 97, allowed PEG derivative 99 to be
selectively conjugated to the C-terminus of the protein
(Scheme 22).
Alternatively, the C-terminus of RNase A was speciﬁcally
functionalized with an azido group following the same
strategy as for the synthesis of protein-based MESNA
thioesters (Scheme 14). Here the target protein was expressed
as an intein fusion protein and attacked by an azido-bearing
a-hydrazine acetamide (100) (Scheme 23).162
Although the Staudinger ligation reaction works well,
products retain a triaryl phosphine oxide moiety. In two
independent reports163,164 traceless Staudinger ligations were
reported in which the used phenylphosphine contained a
cleavable linker (101), which was released once the aza-ylide
attacked the carbonyl group (Scheme 24). The phosphonium
species of the rearranged product 103 was subsequently liberated
during the ﬁnal hydrolysis step. Among the phosphines tested,
105 and 108 exhibited the best reactivity. One limitation of this
ligation method was that it needed to be carried out in organic
or mixed solvents. More recently however, a water soluble
phenylphosphine (109) was developed, which should extend
the applicability of this reaction.165 These traceless variants of
the Staudinger ligation produce a clean amide bond after
coupling, which might improve the biocompatibility of the
prepared bioconjugates. However, the side-products formed
might make puriﬁcation of the product necessary.
One of the ﬁrst applications of the traceless Staudinger
ligation was the assembly of peptide segments synthesized by
SPPS into a ﬁnal synthetic peptide. In contrast to NCL, the
traceless Staudinger ligation does not need a cysteine residue
Scheme 21 Mechanism of the Staudinger ligation.
Scheme 22 Functionalization of PEG with a phosphine moiety suited
for the Staudinger ligation.
Scheme 23 Structure of hydrazine used to introduce an azide into an
intein fusion protein.
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at the ligation site. This freedom was ﬁrst exploited in the total
synthesis of RNase A.166 The full scope and the limitations of
the Staudinger ligation in peptide chemistry still need to be
explored, however. Questions about side chain dependence
and whether or not protecting groups are required remain
unanswered.
The use of the traceless Staudinger ligation has now also
been extended to the immobilization of proteins via a surface-
tethered PEG spacer.167,168 By having phosphine 106 on a
PEG spacer, RNAse A was covalently coupled after which its
immobilization was evaluated by a ribonucleolytic activity
assay and immunostaining.
3.3 Hydrazone and oxime ligation
Instead of using an azide functionality for either a CuAAC or
a Staudinger ligation, proteins and peptides can be site-selectively
conjugated using ketones and aldehydes. These groups are not
commonly present in natural proteins and can react with either
hydrazide (110) or hydroxylamine (114) groups forming a
hydrazone (112) or oxime (115) bond, respectively
(Scheme 25).
Hydrazone chemistry was originally developed to couple
polypeptide fragments together into artiﬁcial proteins.169
Oxime chemistry was ﬁrst employed to modify proteins with
small organic substances,170 but was later also used for the
ligation of polypeptide fragments.171 As a side reaction during
these ligations, amino groups of proteins can form a Schiﬀ
base with the ketones or aldehydes, which can lead to
crosslinked aggregates. However, this side reaction can be
suppressed under acidic conditions, which protonates the
amino groups. Because hydrazides and hydroxylamines are
weaker bases than primary amines, the desired reaction can
still occur. In this way, these coupling reactions can be
performed regioselectively, making them good candidates for
the well-deﬁned formation of bioconjugates without the need
for protecting groups during the conjugation step. Before
elaborating on these conjugation methods, we will describe
how to introduce ketone or aldehyde groups into proteins and
peptides.
When working with glycoproteins, the incorporated
carbohydrate provides a target that can be oxidized under
mild conditions to aﬀord the necessary ketones and aldehydes
within the protein.172–174 Naturally occurring glycosylation
sites are usually well removed from the protein active site
and are readily accessible, making them excellent attachment
sites for polymer chains. Using this method, multiple
attachment sites are generated on the carbohydrate, but all
modiﬁcations are conﬁned to the glycosylation site. When no
glycosylation sites are available, they can be engineered into
the protein.175,176
Another way of introducing ketones or aldehydes into
proteins is to oxidize the N-terminal serine or threonine with
sodium periodate under mild conditions.177 A method with
fewer restrictions on the nature of the N-terminal amino acid
groups is the metal-catalyzed transamination.177 However, the
conditions for this reaction are known to be potentially
harmful to the protein. Also, both oxidation methods have
only been used with varying success together with oxime
coupling.
A more general strategy for the incorporation of ketones in
larger proteins was ﬁrst demonstrated by Tirrell et al., which is
analogous to the earlier described multisite replacement
approach of methionine for azido-homoalanine.178 Brieﬂy,
E. coli’s tRNA-synthetase for phenylalanine was mutated in
such a way that it could also accept p-acetylphenylalanine
(116) (Scheme 26). By feeding phenylalanine auxotrophic
cell lines p-acetylphenylalanine instead of phenylalanine, the
unnatural amino acid was incorporated at all phenylalanine
Scheme 24 Mechanism of the traceless Staudinger ligation together with the structure of the cleavable linker incorporated in the phosphines
tested.
Scheme 25 Hydrazone and oxime ligation.
342 | Chem. Soc. Rev., 2010, 39, 329–353 This journal is c The Royal Society of Chemistry 2010
D
ow
nl
oa
de
d 
on
 0
6 
D
ec
em
be
r 2
01
2
Pu
bl
ish
ed
 o
n 
06
 O
ct
ob
er
 2
00
9 
on
 h
ttp
://
pu
bs
.rs
c.o
rg
 | d
oi:
10.
103
9/B
807
871
H
View Article Online
positions. Schultz et al. created a cell line that introduced
ketones site-speciﬁcally into proteins by using an orthogonal
tRNA and tRNA synthetase couple, which made p-acetyl-
phenylalanine amenable for ribosomal protein production
incorporating it site-speciﬁcally as a 21st amino acid.179
Another possibility is to react speciﬁc residues with ketone-
bearing tags. In one such example, the tyrosine residues of
the protein capsid of the tobacco mosaic virus (TMV) were
reacted with p-acetylbenzenediazonium salt (117).180 The
resulting surface-exposed ketones were coupled to hydroxylamine-
functional PEG. In another example, NHS esters of p-formyl-
benzoic acid (118) were eﬃciently reacted with lysine residues
in order to install aldehydes on the exterior of the MS2
capsid.181 Since this kind of chemistry is not site-speciﬁc,
ketones can be introduced at multiple sites. So, even though
the oxime conjugation itself is bio-orthogonal, constructing
well-deﬁned bioconjugates with this approach can be diﬃcult.
A more controlled way of introducing a ketone functionality
into proteins was described by the group of Francis.182,183
N-terminal amino acids can undergo a transamination
reaction upon exposure to pyridoxal 50-phosphate (120, PLP)
at 37 1C in an aqueous solution (pH 6.5), resulting in the
corresponding pyruvamide derivative (121) (Scheme 27).
Because of the selectivity for the N-terminal amino group,
the ketone is introduced at a single location, leaving the
amines of the lysine side chains unchanged. This reaction
was ﬁrst demonstrated on proteins with an N-terminal glycine,
valine, lysine and methionine,182 and more recently for
N-terminal aspartic and glutamic acid.183 Apart from serine,
threonine, cysteine, tryptophan and proline, it is expected that
this reaction should also be applicable for the remaining
natural amino acids at the N-terminus.
Hydrazide can be easily introduced into PEG184 and be
reacted with ketones and aldehydes to produce a hydrazone
linkage under acidic conditions. The hydrazone linkage is not
very stable but may be reduced with sodium cyanoborohydride
to a more stable alkyl hydrazide (113). In a proof-of-concept,
it was shown that hydrazone formation is compatible with and
orthogonal to CuAAC.185 Poly(norbornene)-based random
copolymers possessing both ketone and azide functionalities
were synthesized using ring-opening metathesis polymerization.
A subsequent one-pot functionalization step with a library of
small organic and biological molecules provided multi-
functional polymers.
Alternatively, a ketone- or aldehyde-functionalized
polypeptide can be attached to a hydroxylamine-bearing
polymer. The oxime bond which is formed is more stable
than the hydrazone linkage and does not need a successive
reduction to produce a stable product. Using oxime chemistry,
Kochendoerfer and co-workers site-selectively attached
two branched polymer chains eﬃciently at two of the four
glycosylation sites of synthetic erythropoiesis protein (SEP).36
The protein was synthesized as four individual peptide
fragments by SPPS, where a non-coded, ketone-bearing
amino acid, Ne-levulinyl lysine, was introduced at the desired
positions. The PEG-based polymer was also synthesized on
solid-phase resin and functionalized with hydroxylamine. The
ﬁnal construct was assembled by ﬁrst coupling the PEG chains
to the target sites with oxime-forming conjugation, followed
by ligation of the four fragments using NCL. In a second
study, this strategy was used to screen several SEP-polymer
bioconjugates for their activity.186 Using the same strategy,
the small anti-HIV protein CCL-5 was site-speciﬁcally
PEGylated.187
Just like hydrazone formation, oxime ligation also has to be
performed under acidic conditions. Since many proteins are
unstable at low pH it would be desirable to perform the
ligation under neutral conditions. This has recently been made
possible by the addition of p-methoxyaniline, which acts as a
nucleophilic catalyst and accelerates the reaction rate.188
Besides solid-phase chemistry, there have been other
approaches developed for the convenient functionalization of
polymers with a hydroxylamine moiety. One example is the
solution-based displacement of the terminal alcohol group
by N-hydroxyphthalimide under Mitsunobu conditions.180
Another example used tert-butyloxycarbonyl (Boc) protected
hydroxylamine initiators for ATRP.189 Using such controlled
radical initiators, HEMA, NIPAAm and poly(ethylene glycol)
methacrylate (PEGMA) were polymerized with low poly-
dispersities (PDI). Deprotection with triﬂuoroacetic acid
liberated the hydroxylamine moiety, allowing a chemospeciﬁc
coupling with Ne-levulinyl lysine-functionalized BSA.
In a further variation of the oxime coupling method, the two
moieties used, i.e. the hydroxylamine and the ketone or
aldehyde switch places. In this opposite approach, a PEG-based
polyamide chain was functionalized with terminal serine
residues, after which the alcohol functions were oxidized with
periodate into glyoxylyl groups.190 Complementary to this, a
hydroxylamine group was attached to the N-terminus of a
peptide using Boc-aminooxyacetyl-N-hydroxysuccinimide
during SPPS. In the ﬁnal step, a well-deﬁned bioconjugate
was synthesized by coupling the synthetic polymer to the
peptide through the formation of an oxime bond. In the
same way, an aminooxyacetic acid was protected with
acetone and incorporated into CCL-5 using SPPS.191 After
deprotection, the peptide was conjugated to an aldehyde-
functionalized PEG.
Scheme 26 Structures of a ketone-containing amino acid and ketone-
bearing tags.
Scheme 27 Introduction of a ketone moiety to the N-terminus using
PLP.
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Using the same set-up, dendrimers were functionalized with
a peptide.192 An amine-functional dendrimer was decorated
with ketone groups by coupling levulinic acid using a carbo-
diimide. The twenty-mer peptide Glu–Tyr–Leu–Asn–Lys–Ile–
Gln–Asn–Ser–Leu–Ser–Thr–Glu–Trp–Ser–Pro–Ala–Ser–Val–Thr
was equipped with an N-terminal aminooxyacetic acid residue
during SPPS and subsequently cleaved from the resin. Oxime
ligation in an aqueous phosphate buﬀer aﬀorded an average
dendrimer loading of 63%. Attempts to fully load the
dendrimer failed, probably due to steric crowding.
This methodology has also been translated to the chemo-
selective surface immobilization of peptides. Surface-bound
hydroquinone was selectively oxidized to the ketone bearing
benzoquinone, after which hydroxylamine-functional peptides
were coupled via oxime ligation.193 Because of the incorporated
redox activation step, the extent of immobilization could be
modulated by changing the electrochemical potential of the
surface. Alternatively, oxime ligation can be used together
with lithography for surface patterning (Scheme 28). Surface-
bound hydroxylamine groups were protected with nitro-
veratryloxycarbonyl (122, NVOC), which were selectively
removed by shining ultraviolet light through a patterned
photomask.194 A peptide bearing an N-terminal ketone (124)
was subsequently immobilized according to the predetermined
surface patterns.
3.4 Miscellaneous copper-free click reactions
Several additional copper-free click reactions have been
developed within chemical biology in recent years. Several
methods have been developed to increase the reactivity of
dipolarophiles towards azides in 1,3-dipolar cycloaddition.
Prime examples are the oxanorbornadiene-based tandem
cycloaddition–retro-Diels–Alder (crDA) reaction (126),195
the diﬂuorinated cyclooctyne- (129)196 and dibenzocyclooctyne-
based (132)197 strain-promoted azide–alkyne [3 + 2] cyclo-
additions (Scheme 29).
All three reactions proceed with high yields and without the
formation of interfering by-products. When comparing the
extent of functionalization of an azide-containing coating,
both the oxanorbornadiene-based crDA reaction and dibenzo-
cyclooctyne-based cycloaddition gave better results than the
CuAAC and Staudinger reactions.198 Solubility in aqueous
solutions, however, remains an issue, with the oxanorbornadiene
being the most hydrophilic. Examples of bioconjugations
using these reactive groups are still limited,199 and most studies
focus on the labeling of proteins with small organic probes.
From these studies, however, it is apparent that these methods
are good candidates for selective bioconjugation.
Lin and co-workers reported a method using tetrazoles
(135), which generate nitrile imines (136) under UV light that
can subsequently react with substituted alkene dipolarophiles
(Scheme 30).200 This photoactivated 1,3-dipolar cycloaddition
reaction was used to selectively label a genetically encoded
alkene-containing protein (137). In another recent example of a
1,3-dipolar cycloaddition as a bioconjugation tool, norbornene-
modiﬁed DNA (139) was smoothly reacted with several
modiﬁed nitrile oxides (140).201
Another bioorthogonal coupling reaction, which was
recently used for C-terminal PEGylation, is based on the
thioacid/azide amidation reaction.202 In short, protein splicing
of a recombinant protein yielded the small ubiquitin protein
with a thioacid group at the C-terminus (142), which was
subsequently selectively amidated by the electron-deﬁcient
sulfoazide 143 (Scheme 31). Only mono-PEGylated product
was obtained, conﬁrming the chemoselectivity of the reaction.
However, the reaction was accompanied by some hydrolysis
resulting in a yield of only about 65%.
Diels–Alder reactions are now also being explored as
possible conjugation methods (Scheme 32). In one example,
an inverse electron demanding Diels–Alder reaction between
trans-cyclooctenes (145) and tetrazines (146) was followed by a
retro-[4 + 2] cycloaddition, producing the conjugated product
and nitrogen in quantitative yield.203,204
Scheme 28 Surface patterning using oxime ligation and the photo-
labile protection group NVOC.
Scheme 29 Examples of copper-free click reactions based on
1,3-dipolar cycloaddition with azides.
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Very fast conjugation of macromolecular blocks was shown
to be possible between the thiocarbonate endgroup of a RAFT
polymer (148) and a cyclopentadienyl-functionalized polymer
(149).205 This retro-Diels–Alder reaction can be accelerated by
using triﬂuoroacetic acid (TFA) as a catalyst, resulting in
quantitative yields in just a few minutes (Scheme 33).
4. Grafting to using non-covalent interactions
Instead of covalently coupling polymers and proteins, bio-
conjugates can also be prepared by strongly coordinating
polymers to proteins. This can be done by the use of cofactors.
Cofactors are small organic molecules that are positioned in
the active site of certain proteins and they are usually of great
importance for the activity of these proteins. The cofactor can
be removed from the protein and attached to a polymer. By
simple mixing of the protein and the polymer-functionalized
cofactor, a bioconjugate is created when the cofactor is
reconstituted in the pocket of the protein. This strategy is
eﬃcient, provided that the modiﬁcation of the cofactor does
not hinder the complexation with the protein.
This strategy was ﬁrst explored using the well-studied
biotin–(strept)avidin system. The cofactor biotin (vitamin
B7) has an aﬃnity for avidin (KaE 10
15 M1) or streptavidin
(Ka E 10
13 M1) which is so high that it can be regarded as
irreversible.206 The naturally occurring carboxylic acid of
biotin provides an easy way to couple it to pre-made
polymers207,208, block copolymers,209,210 dendrimers,211
polymer brushes212 or for incorporation into crosslinked
thin ﬁlms.213,214 In order to circumvent the need for post-
polymerization modiﬁcations, biotin can already be incorporated
into the initiator that is used for the synthesis of the polymer.
This approach has been carried out for azonitrile initiators,215
cyanoxyl-mediated polymerization,216,217 ATRP218–220 and
RAFT.221,222 Because the acid group is not involved in the
complexation with the protein, these modiﬁcations do not
change the binding characteristics much. To facilitate a
smooth incorporation of the cofactor into the protein, a
hydrophilic207,211,218–220 or hydrophobic208,209,213,214 spacer
can be included between biotin and the polymer chain.
Similarly, one of the carboxylic acids of the heme cofactor
protoporphyrin IX was used for the attachment of a poly-
styrene chain. The heme-functionalized polymer was
subsequently reconstituted into the HRP enzyme223 or the
oxygen-binding protein myoglobin (Mb).224 The resulting
giant amphiphiles were found to assemble into spherical
aggregates, presumably vesicles. When this method was used
to attach a PS-b-PEG copolymer to HRP and Mb, the
obtained protein-containing ABC triblock formed a variety
of more complicated aggregate structures.225 In all three
examples, a hydrophilic spacer was built between the hydro-
phobic polystyrene and the cofactor to assure the compatibility
between polymer and protein. Even so, the reconstitution had
a negative eﬀect on the biological activity of both heme
proteins. In the case of HRP, the enzymatic activity decreased.
For Mb, the stability of the oxy complex was reduced. This
negative eﬀect is probably due to a disturbed binding of the
cofactor in the protein or a restricted access of substrates to
the active site caused by the presence of the polymer chain.
Scheme 30 Examples of copper-free click reactions based on
1,3-dipolar cycloadditions with nitrile imines and nitrile oxides.
Scheme 31 C-terminal PEGylation of ubiquitin using the thioacid/
azide amidation reaction.
Scheme 32 Conjugation reaction between trans-cyclooctene and
tetrazine.
Scheme 33 Conjugation of two macromolecular blocks though a
Diels–Alder reaction.
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This illustrates that even when the position of polymer attach-
ment is precisely known and controlled, it can still have a
negative eﬀect on protein activity when it is near the active site.
In the area of stimuli-responsive drug delivery, non-covalent
interactions were used in the formation of hydrogels via the
interaction of PEG-based heparin-functionalized star-polymers
and the dimeric protein vascular endothelial growth factor
(VEGF), which can bind heparin and acted as a crosslinker
during gel formation.226 Stimuli-responsive erosion of the
hydrogel was triggered after exposure to particles decorated
with the VEGF receptors that bound the VEGF protein.
When loaded with drugs, this hydrogel could therefore
potentially be used for targeted delivery on the basis of
ligand–receptor interactions.
5. Grafting from
We have seen that high requirements are put on the coupling
chemistry when using the grafting to strategy, especially with
regards to yield and speciﬁcity. Instead of conjugating a
preformed polymer to a protein or peptide, a polymer can
also be grown from these biological molecules. Alternatively,
an amine terminal polymer can act as a macroinitiator of a
polypeptide using ROP of amino acid N-carboxyanhydrides
(NCA). The beneﬁt of these strategies is that the need for a
conjugation between macromolecules is averted, because only
a small initiator moiety needs to be introduced to either the
biological component or the polymer. The lower steric
hindrance during the functionalization of the macromolecules
simpliﬁes the procedure. Furthermore, the product can be
easily puriﬁed once the polymer is grown from the macro-
initiator, as only the unreacted monomer has to be removed,
as opposed to a preformed polymer.
5.1 Peptide macroinitiators
One of the ﬁrst examples of this strategy was reported by
Bo¨rner et al. who used an oligopeptide as a macroinitiator.227
The pentapeptide Gly–Asp(t-Bu)–Gly–Phe–Asp(t-Bu) was
synthesized by SPPS and the N-terminus was acylated with
2-bromopropionic acid, a standard initiator for ATRP. Next,
the oligopeptide initiator was carefully cleaved from the solid
support so as to avoid side group deprotection, and used for
the ATRP of n-butyl acrylate. The resulting oligopeptide–
poly(n-butyl acrylate) block copolymer had a number average
molecular weight (Mn) of 10 000 g mol
1 and a PDI of
approximately 1.19. However, interactions between the copper
catalyst and the oligopeptide were observed, which caused a
slow polymerization rate and a decrease of propagating
radicals during the polymerization. Other reports described
the same eﬀects and slightly higher PDI’s (1.22–1.37) when
using this strategy.228 This observation was ascribed to a
low initiator eﬃciency of the amide-containing initiator. To
overcome these drawbacks, oligopeptide-based initiators
were synthesized for RAFT polymerizations. Using this
copper-free controlled polymerization method, n-butyl acrylate
(PDIB 1.1)229,230 NIPAAm (PDIB 1.2)230 and oligo(ethylene
glycol) acrylate (OEGA) (PDI B 1.2)230 were polymerized
from peptide macroinitiators.
Instead of functionalizing the N-terminus, amino acid side
groups can be used as initiation sites. A peptide-based
amphiphilic ABA triblock copolymer was prepared by the
solid phase synthesis of a peptide with the sequence
Ser–Ala–Gly–Ala–Gly–Glu–Gly–Ala–Gly–Ala–Gly–Ser–Gly.231
Before the peptide was cleaved from the solid support, the
alcohol side groups of the two serines were functionalized with
an a-bromo ester moiety to create a bifunctional ATRP
initiator. Using living radical polymerization, methyl
methacrylate (MMA) was polymerized in solution yielding a
well-deﬁned ABA triblock copolymer. Upon suspension of
this amphiphilic triblock in a mixture of tetrahydrofuran and
water, followed by the removal of tetrahydrofuran, poly-
mersomes were formed. Alternatively, Fmoc-protected serine
was ﬁrst modiﬁed with an ARTP232 or nitroxide-mediated
radical polymerization (NMP) initiator233 and then incorporated
into a peptide by SPPS. This strategy allows for a polymer
modiﬁcation at a speciﬁc site without having to rely on a
distinctly diﬀerent chemistry of the targeted residue within the
sequence.
Biesalski et al. prepared cyclic peptides with an alternating
D- and L-amino acid sequence that self-assemble into hollow
nanotubes.234,235 After the preparation and cyclization of the
peptide on the solid support, the three available lysine residues
were functionalized with an a-bromo ester group and the
cyclic peptide initiator was cleaved from the resin. In solution,
the ATRP initiating sites were exposed on the outer surface of
the peptide nanotubes and polymerization yielded peptide
assemblies decorated with polyNIPAAm234 or polybutyl-
acrylate.235
Instead of synthesizing the peptide on the solid support and
sequentially performing the polymerization in solution,
Wooley and co-workers have shown that the entire bioconjugate
can be synthesized on the resin. By functionalizing the
N-terminus of a peptide with an alkoxyamine, a poly(acrylic
acid)-b-poly(methyl acrylate) (PAA-b-PMA) copolymer was
synthesized via NMP while keeping the macroinitiator on the
resin.236 This method has also been extended to ATRP,237,238
showing the general applicability of this strategy.
5.2 Protein macroinitiators
Macroinitiations from complete proteins were initially
conducted by simple free radical polymerization in the
presence of proteins. The initiators are generally redox-,239
thermally-240 or radiation-induced.241 This creates radicals on
the protein surface from which polymers were grown. In these
examples, however, the grafting of the polymer occurs at
completely random positions and there is no control over
the amount of polymer chains attached.
This approach was made more speciﬁc by Matyjaszewski
et al. by attaching 2-bromoisobutyryl bromide to the lysine
residues of a-chymotrypsin (aCT).242 Up to 8 initiating
moieties were coupled from which PEGMA chains with a
low PDI were grown via ATRP. However, the exact location
of attachment could not be controlled.
Functionalization of cysteines gives better control over the
location of the initiating site. For this purpose, BSA was ﬁrst
reduced. This freed three cysteines for functionalization with a
346 | Chem. Soc. Rev., 2010, 39, 329–353 This journal is c The Royal Society of Chemistry 2010
D
ow
nl
oa
de
d 
on
 0
6 
D
ec
em
be
r 2
01
2
Pu
bl
ish
ed
 o
n 
06
 O
ct
ob
er
 2
00
9 
on
 h
ttp
://
pu
bs
.rs
c.o
rg
 | d
oi:
10.
103
9/B
807
871
H
View Article Online
pyridyl disulﬁde or maleimide ATRP initiator from which
NIPAAm, PEGMA and dimethylaminoethyl methacrylate
(DMAEMA) chains were grown.243,244 In the case of the
pyridyl disulﬁde initiator, the disulﬁde bond between BSA
and the polymer was reduced after polymerization. The
detached polyNIPAAm was analysed by gel permeation
chromatography (GPC) indicating a PDI of 1.34. This work
was reproduced for the macroinitiation of PEGMA and
NIPAAm using RAFT polymerization.245,246 This approach
was also applied to a lysozyme mutant bearing a single
cysteine, which was functionalized with an ATRP initiator.243
This macroinitiation strategy can be combined with a non-
covalent coupling strategy. This was demonstrated using the
abovementioned biotin–streptavidin couple. A biotinylated
initiator was complexed in the streptavidin binding pocket.
Subsequently macroinitiation from the protein complex was
performed.247
5.3 Polymer macroinitiators
In the section concerned with SPPS, we saw that a peptide can
be grown from a polymer using solid phase synthesis in a
stepwise fashion.50–56 Using amine functionalized polymers
(151), it is also possible to initiate the ROP of amino acid
NCAs (152), forming poly(amino acids) (Scheme 34). Recent
reviews have extensively discussed the synthesis of linear
peptide–polymer block copolymers synthesized in this manner
and the reader is referred to these papers for a more detailed
overview.248,249
The major drawback of the conventional amine-initiated
NCA polymerization is that it is plagued by chain-breaking
transfer and termination reactions, which prevent the
poly(peptide) chain length from being controlled accurately.
This problem can be overcome by using high vacuum techniques
in order to create and maintain the conditions necessary for
the living polymerization of NCAs with primary amines.250
A second way to get better control over the poly(peptide)
synthesis is to replace the free primary amine initiator with its
corresponding amine hydrochloride salt.251
Enhanced control of the NCA polymerization can also be
obtained by using a zero-valent nickel complex (154) as the
initiator.252 The transition metal mediates in the addition of
monomers to the active polymer chain-end (155), suppressing
chain-transfer and termination side reactions (Scheme 34).
More complex architectures are also accessible by using
branched star-shaped macroinitiators. In one example, a
star-shaped PEG with four terminal amines was used as a
macroinitiator for the ROP of g-benzyl-L-glutamate NCA.253
The outer poly(g-benzyl-L-glutamate) blocks yielded a self-
assembling star-shaped polymer–peptide copolymer. Similarly,
a triarm, star-shaped PS was synthesized using ATRP.254 The
three terminal bromides were ﬁrst replaced by azides and then
transformed via a Staudinger reduction. The resulting amine-
terminated triarm was used to grow three poly(g-benzyl-L-
glutamate) arms onto the branched structure.
In another example of this macroinitiator strategy, a dual
initiator was synthesized containing a primary amine and a
nitroxide group.255 ROP yielded poly(g-benzyl-L-glutamate)
with high structural control. Macroinitiation of styrene by
nitroxide-mediated controlled radical polymerization yielded a
block copolymer with a polydispersity around 1.1. Both
polymerizations were also successfully conducted in one pot
without intermediate isolation owing to the high compatibility
of both polymerization techniques.
6. Grafting through
An interesting peptide–polymer bioconjugate architecture
places the peptide moieties as side chain functionalities on a
polymer backbone. When aiming for these comb-shaped
structures, the grafting to strategy can fall short as it is very
diﬃcult to achieve quantitative functionalization. To over-
come this problem, another strategy has been developed in
which the peptide is attached to the monomer unit. Therefore,
after polymerization, every monomer is inherently functionalized.
The disadvantage of this strategy is that synthesizing peptide-
functionalized monomers is not trivial, and compatibility
issues between the polymerization technique and peptide
moiety have to be taken into account.
As one of the ﬁrst examples, the dipeptide Leu–Ala was
introduced to both methacrylamide256 and methacrylate257
units, and polymerized by free radical polymerization. Extension
of this procedure to an acrylamide with a Leu–Ala-based
oligopeptide side chain, aﬀorded an oligomer with a degree
of polymerization between 3–8.258 The peptide moiety of the
resulting product maintained its a-helical structure after
polymerization in chlorobenzene, but was lost in DMF.
In another early example, norbornene-derived peptide-
functionalized monomers with the cell adhesive sequences
Gly–Arg–Gly–Asp and Ser–Arg–Asn (158) were polymerized
via ring-opening metathesis polymerizations (ROMP) using a
Grubbs’ catalyst (Scheme 35).259 Incorporation of a
PEG-functionalized monomer (157) was found to prevent
premature precipitation of the polymer during the course of
polymerization and yielded a water soluble product. In a
further study, a polymer substituted with a
Gly–Arg–Gly–Asn–Ser peptide was shown to be signiﬁcantly
more active than the free peptide.260 This result demonstrates
that the increased local concentration of peptides in comb-shaped
bioconjugates can lead to multivalent interactions and thereby
signiﬁcantly enhance the observed biological activity. In a
further example of the use of the Grubbs’ catalyst, dipeptide
oleﬁn monomers (160) were polycondensated via acyclic diene
metathesis (ADMET) (Scheme 35).261
Scheme 34 ROP of NCAs using a primary amine initiator and a
nickel catalyst. bipy = 2,20-bipyrydine; COD = 1,5-cyclooctadiene.
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Isocyanide moieties have also been introduced as monomeric
units on the N-terminus of oligopeptides.262,263 These monomers
were subsequently polymerized using a nickel catalyst and
formed rigid b-helical rods. This rigidity was caused by the
hydrogen bonding network formed between the amide groups
of the peptide side chains. Moreover, it was shown that the
handedness of the helix could be steered by changing the
enantiomeric conﬁguration of the peptide side chain.
Introduction of a hydrophobic PS block into these peptide-
based materials furthermore resulted in the formation of
polymersomes.264
The recent emergence of controlled radical polymerizations
has provided a new momentum to the ﬁeld of peptide-
functionalized monomers by presenting better control over
the polymerization reaction. The possibilities were ﬁrst
illustrated with the ATRP polymerization of a methacrylate
coupled to Val–Pro–Gly–Val–Gly, a pentapeptide sequence
derived from the structural protein tropoelastin, which exhibits
LCST behaviour (162) (Scheme 36).265 The polymerization of
this monomer with the initiator ethyl-2-bromo-2-methyl-
propionate (163, Ebib) proceeded in a controlled fashion
and yielded polymers with a reasonably low PDI (1.25). Using
a bifunctional PEG-based macroinitiator (165) it was even
possible to synthesize triblock copolymers with fairly narrow
molecular weight distribution (PDI 1.27). LCST of this ABA
type block copolymer could be inﬂuenced by changing the
degree of polymerization, polymer concentration, and pH.266
Using the same bifunctional initiator, monomers with an
Ala–Gly–Ala–Gly side chain were also polymerized in a
controlled manner (PDI 1.12).267 The living character of the
ATRP process was furthermore illustrated by extending the
block copolymer with a further MMA block via an in situ
macroinitiation (PDI 1.17).
It was possible to polymerize even bulkier peptide-
functionalized monomers with ATRP. The cyclic b-sheet
forming decapeptide gramicidin S was modiﬁed with a
methacrylate handle and subsequently polymerised viaATRP.268
Although the polymerization was very slow, ﬁrst-order kinetics
were observed and a low PDI was obtained (1.09). The
secondary structure of the peptide moiety was retained within
the resulting polymer, as indicated by IR spectroscopy.
The study with the Val–Pro–Gly–Val–Gly-functionalized
methacrylate monomer was repeated with RAFT.269 Using
this technique, polymers with a higher degree of polymerization
and lower PDI’s were isolated. In ATRP the copper catalyst
might complex with the amide bonds in the peptide side chains
and be deactivated. The absence of this peptide-induced
deactivation in RAFT explains the improved polydispersities
which were obtained.
7. Conclusions
In conclusion, the combination of synthetic polymers with
polypeptides has opened the path towards a great new set of
materials with unprecedented properties obtained in part
because of the intrinsic (bio)functionalities of proteins and
peptides. For many years, applications of polypeptide-
polymer bioconjugates have been focussed on the ﬁeld of drug
delivery. New applications which are rapidly developing
include diagnostics, tissue engineering and bioactive surfaces.
The self-assembly properties of certain types of bioconjugates
might make them useful components for nanotechnological
applications, although this ﬁeld is still on a more
fundamental level.
As these applications become ever more sophisticated, the
requirement for selective and even speciﬁc coupling methods
increases. This development has been illustrated in this review,
where we have shown the advancement from early day coupling
methods based on nucleophilic attacks of amines present in
proteins and peptides, to the introduction of bio-orthogonal
‘click’ reactions. In the future, this trend will only continue
into the expansion of more facile and widely applicable
bio-orthogonal conjugation methods.
Scheme 35 ROMP and ADMET of peptide-functionalized
monomers.
Scheme 36 ATRP of peptide-functionalized monomers.
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